Journey Medical Corp DERM.OQ DERM.O is expected to show a fall in quarterly revenue when it reports results on March 26 for the period ending December 31 2024
The Scottsdale Arizona-based company is expected to report a 6.8% decrease in revenue to $14.213 million from $15.26 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Journey Medical Corp is for a loss of 35 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Journey Medical Corp is $10.00, above its last closing price of $5.74.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.14
-0.15
-0.17
Missed
-15.3
Jun. 30 2024
-0.14
-0.14
-0.17
Missed
-18.6
Mar. 31 2024
-0.23
-0.23
-0.53
Missed
-125.5
Dec. 31 2023
-0.09
-0.08
-0.12
Missed
-56.5
Sep. 30 2023
-0.11
-0.15
0.80
Beat
616.1
Jun. 30 2023
-0.35
-0.33
-0.29
Beat
13.4
Mar. 31 2023
-0.45
-0.45
-0.57
Missed
-27.6
Dec. 31 2022
-0.47
-0.60
Missed
-28.6
This summary was machine generated March 24 at 20:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)